Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOC1021 (Dubodencel) in Glioblastoma
NCT04552886Phase 1Completed
- Sponsor
- Cooper University Health Care
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of dubodencel in glioblastoma (GBM) (4 arms), sponsored by Cooper University Health Care. Primary endpoint: Safety and potential toxicity of Th-1 dendritic cell immunotherapy at 2 years. Started Oct 2021; status: completed.
02
Drugs
dubodencel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04552886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552886.